Recent progress in brain imaging offers great potential for anaesthesia research. 46 Among the most important imaging modalities for mapping human brain activation are positron emission tomography (PET) and functional magnetic resonance imaging (fMRI). Both techniques are based on mapping haemodynamic or metabolic changes that are a direct consequence of alterations in neuronal activity.
caused by well-de®ned stimuli or tasks. These studies are usually called activation studies. The analysis of the measured data is based on statistical comparison of the measurements obtained during different conditions (e.g. performing a task vs resting) reveals regional stimulus or task-related changes in CBF or CMRGlu. In contrast to these cognitive activation studies, PET studies of anaesthetic action in the human brain are often based on comparing physiological variables measured under different states of anaesthesia. Regional alterations in CBF and CMRGlu are assumed to re¯ect changes in regional neural activity and may provide neuroanatomical evidence for behavioural responses associated with sedation and anaesthesia.
The theoretical basis for regional (r)CBF measurements with PET is the work by Kety, 38 39 which allows assessment of rCBF in laboratory animals. The animal tissue autoradiographical methods of rCBF measurements are adapted for use with PET. 35 In human studies, the tracer of choice for CBF mapping is 15 O-labelled water (H 2 15 O). 36 This molecule can diffuse freely across the blood±brain barrier. Because of its short half-time (2 min) the tracer allows the performance of repeated measurements in a single study session and the use of a variety of experimental designs. After injection of a single dose of H 2
15
O PET images are immediately acquired to obtain the¯ow-dependent accumulation and disappearance of the radiotracer and to calculate maps of rCBF.
PET measurements of CMRGlu in man are based usually on [ 18 F]¯uorodeoxyglucose ( 18 FDG) . 2 This tracer is taken up by brain neurones depending on their functional state, as if it were glucose. It is phosphorylated in the brain tissue by hexokinase to FDG-6-phosphate. Unlike glucose, FDG-6-phosphate becomes intracellularly trapped for at least 45 min without being further metabolized. Uptake of FDG and metabolic trapping of the FDG-6-phosphate is nearly complete about 30 min after injection of the tracer. After this period PET scans are obtained and blood samples are collected to measure glucose and FDG concentrations in plasma as a function of time. The amount of radioactivity in each region of the brain is related to the glucose uptake and the glucose metabolism in this region. As glucose is the primary substrate for brain cells, the measured radioactivity in any particular region represents the glucose metabolism in this area. However, this technique has some limitations. Because of the long half-time (110 min) and the long uptake period, repeated scans are dif®cult to perform and a constant neurobehavioural state has to be ensured over a long period. For this reason, many drug studies have been performed using CBF rather than CMRGlu as an index of local cerebral activity. 36 
Receptor imaging
Because of the biochemical selectivity of PET, neurotransmission processes can be investigated that occur at very low concentrations, typically in the nanomolar to the picomolar range. Speci®c radioactive tracers can be designed that bind selectively to molecular targets, such as receptors or proteins involved in the synthesis or metabolism of neurotransmitters. A variety of radiolabelled ligands have been designed for tracing different signalling systems in the human brain, including the GABAergic/benzodiazepine, cholinergic, opioid, and monoaminergic system. 29 PET therefore offers the unique possibility to identify putative molecular targets of anaesthetics and to probe their action on neurochemical processes in vivo.
Functional magnetic resonance imaging
Most fMRI studies are based on measuring changes in the blood oxygenation level-dependent (BOLD) contrast that arise from the paramagnetic properties of the deoxyhaemoglobin molecule. 25 48 A decrease in the regional deoxyhaemoglobin concentration increases the effective transverse relaxation time, T2*, that can be mapped by using T2*-weighted MRI techniques. Neural activation is accompanied by a regional increase in blood volume, blood ow, and oxygen consumption. 14 An increase in blood¯ow produces a decrease in deoxyhaemoglobin concentration, whereas an increase in oxygen consumption or venous blood volume has the opposite effect. The BOLD contrast therefore depends on changes in both cerebral haemodynamics and oxidative metabolism. When periods of neural stimulation and of rest are compared, the BOLD signal typically is increased during periods of neural stimulation indicating that the haemodynamic response to the stimulus is the dominant variable in BOLD-based fMRI.
PET studies of anaesthetic action

Studies of regional cerebral glucose metabolism and rCBF
Several investigators have used PET techniques to measure rCBF 15 24 57 and CMRGlu to identify neural structures related to anaesthetic actions in the human brain.
3 4 6 Using the 18 FDG PET technique Alkire and co-workers studied the effects of iso¯urane, halothane, and propofol on brain glucose metabolism.
3 4 6 In these studies the anaesthetics were incrementally titrated to the point of unresponsiveness and brain glucose metabolism was investigated during steady-state conditions. At the same clinical endpoint, similar results in whole-brain glucose metabolism were obtained for the three agents. Halothane decreased wholebrain glucose metabolism by 40%, iso¯urane by 46%, and propofol by 55%. This general decrease in metabolic activity is believed to re¯ect the reduced synaptic activity across the brain in the anaesthetic state. This hypothesis is con®rmed by a linear correlation of the metabolic reduction in various EEG variables during propofol and iso¯urane anaesthesia. 5 It is therefore reasonable to assume that the general metabolic reduction associated with the anaesthetic state is a determinant of anaesthetic depth. However, research by Alkire's group did not show only a general cerebral depression, it also revealed subtle differences in regional metabolic reduction caused by the volatile agents. In addition, in comparison with volatile anaesthetics these differences were more pronounced for propofol, consistent with the proposal that volatile agents and propofol act through different molecular mechanisms. 27 42 Iso¯urane anaesthesia caused a nearly uniform cortical and subcortical metabolic reduction. 4 Regional shifts in the pattern of brain glucose metabolism were observed for halothane with a more speci®c metabolic suppression in the thalamus, basal forebrain, cerebellum, occiput, and limbic system. 6 In contrast to volatile anaesthetics, the metabolic reduction caused by propofol was not uniform throughout the brain.
3 It was more pronounced in the cortex (58%) than in subcortical regions (48%). Furthermore, propofol tended to suppress glucose metabolism in the cerebral cortex, especially in the temporal and occipital regions, to a greater extent than inhalation agents. In addition, compared with halothane, propofol caused signi®cantly less metabolic suppression in the basal ganglia and midbrain regions.
Inhaled anaesthetics may cause unconsciousness by altering neuronal activity in speci®c regions of the CNS. Therefore, the next logical step taken by Alkire and his colleagues was to compare the regional patterns of metabolic depression caused by iso¯urane and halothane.
7 Such an analysis was expected to reveal brain regions that were affected to a similar extent. If those brain areas had existed, it would have been reasonable to assume that these regions would mediate the state of inhalation anaesthesia. And, in fact, Alkire's analysis revealed brain regions, which differed in their functional activity between the awake state and the drug-induced unconsciousness, irrespective of each particular effect of the agent on regional cerebral metabolism. Both agents caused a speci®c relative reduction of regional cerebral glucose metabolism primarily in the thalamus and also in the midbrain reticular formation, basal forebrain, cerebellum, and occipital cortex. These ®ndings clearly underline the importance of speci®c neural structures in mediating drug-induced loss of consciousness and re¯ect the importance of the thalamus as a target in inhibition of the¯ow of information to the cortex. Similar mechanisms in mediating anaesthesia were proposed by Angel on the basis of in vitro experiments using rats.
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The results of recent H 2 15 O PET studies further underpin the hypothesis that speci®c neural networks contribute to the behavioural changes produced by anaesthetics.
15 24 Fiset and co-workers investigated rCBF during graded changes of propofol anaesthesia. Consistent with the general reduction in glucose metabolism reported for propofol by Alkire, 3 Fiset found a 20.2% overall decrease in absolute CBF, indicating an overall decrease in cortical neural activity.
This effect was particularly pronounced in the medial thalamus, posterior cingulate, basal forebrain, and in the occipitoparietal association cortices. In addition, the authors found a strong correlation between the level of consciousness and the reduction in CBF in the thalamus, basal forebrain, and occipitoparietal regions. Furthermore, a signi®cant covariation between the thalamic and midbrain blood¯ow changes was observed, suggesting a close relationship between these structures. These results indicate that propofol preferentially affects brain activity in areas that are known to be linked to the control of consciousness, associative functions and autonomic control. 51 These ®ndings have been con®rmed recently by the same group of authors. 15 In addition to the previous investigation a stimulus-induced study design was chosen. Changes in rCBF were measured in order to determine whether different levels of propofol anaesthesia would affect subcortical and cortical processing of vibrotactile stimuli in a different way. This study showed a dose-dependent impairment of the processing of vibrotactile stimuli in the brain. Sedative concentrations of propofol already caused a suppression of the rCBF response in the somatosensory cortex, whereas the stimulus-induced thalamic activation was still present. Suppression of rCBF response in this area was merely found when volunteers had lost consciousness. These differential effects may re¯ect sequential effects on the complex thalamocortical system and may be responsible for dose-dependent behavioural changes. The ®nding that thalamic activation only disappeared in unconscious subjects provides further evidence for the importance of this particular part of the brain in mediating drug-induced unconsciousness.
Speci®c changes in rCBF were also reported for midazolam. 13 55 56 Beside the well-known global decrease in CBF, midazolam infusion resulted in CBF reductions in discrete brain regions, including the prefrontal cortex, the superior frontal gyrus, the anterior cingulate gyrus, parietal and temporal association areas, the insular cortex, and the thalamus. 35 56 These areas subserve arousal and memory processes, particularly the prefrontal cortex. 51 It was proposed that the affected regions were most likely involved in mediating amnesia produced by midazolam. 56 Most of the brain imaging studies cited above have underscored the importance of the thalamus as a putative macroscopic target of anaesthetic action. It is therefore not surprising that benzodiazepines may also produce their substantial sedative effects via that target. In the study by Veselis the largest decrease in rCBF during deep midazolam sedation was found in the thalamus. Other human PET studies, related to the action of benzodiazepines, also demonstrated large decreases in regional neural activity in the thalamus after lorazepam 45 60 or midazolam 13 administration.
Like midazolam, low doses of propofol are known to produce substantial anterograde memory impairment. PET imaging revealed signi®cant dose-related CBF decreases in the prefrontal and parietal cortices similar to those obtained for midazolam. 57 This may indicate that both drugs, though structurally different, produce their behavioural effects by affecting the same neural networks.
In summary, besides a dose-dependent general decrease in whole-brain activity during anaesthesia, the PET imaging studies indicated similar key brain structures involved in the effects of anaesthetics. Furthermore, speci®c anatomical regions were identi®ed that appear to be crucial for speci®c behavioural changes caused by anaesthetics, such as amnesia or loss of consciousness. Very low doses of anaesthetics seemed to affect cortical areas preferentially, mainly in the association cortices, and with a further increase in their dosage the primary sensory cortices. This caused disturbances in attention and memory processes, while subjects were still awake and able to respond to commands. Higher doses of anaesthetics did not only affect cortical but also subcortical brain structures. In particular, the thalamus and the midbrain reticular formation appeared to be key targets for drug-induced loss of consciousness.
Studies of receptor function
Although PET studies provide a macroanatomical picture of cerebral anaesthetic action, they provide no information about why certain brain areas are more or less sensitive to anaesthetics. Indirectly, this information can be obtained by comparing the results of in vivo studies with ex vivo studies of receptor distribution but the use of modern PET ligand technology appears to be a more promising approach.
There is strong evidence from in vitro studies, that anaesthetics may act via GABAergic mechanism. 26 Positron emission tomography and functional magnetic resonance imaging receptors in the intact brain. Using this technique, iso¯urane has been shown to increase receptor-speci®c radioligand binding, dependent on GABA A receptor density. 32 This observation provides strong support for the hypothesis that the GABA A receptor is involved in mediating the action of volatile anaesthetics in humans. In addition, the radioligand binding measured during anaesthesia at 1.5 MAC (minimum alveolar concentration) was signi®cantly greater than at 1.0 MAC, indicating a dose-related effect of iso¯urane on GABA A receptor ligand binding (Fig. 1) .
Alkire and co-workers 8 correlated the data from their in vivo studies 3 7 reported recently with regional distribution patterns of various human receptor binding site densities obtained from previous ex vivo studies. 16 22 64 The regional reduction in glucose metabolism caused by propofol exhibited a signi®cant correlation (r=±0.86, P<0.0005) with the distribution of the benzodiazepine binding site densities, which means that metabolism decreased more in regions with higher receptor levels (Fig. 2) .
In contrast to the link between changes in glucose metabolism caused by propofol and the benzodiazepine receptors the metabolic reduction observed during iso¯ur-ane anaesthesia revealed no correlation with the distribution of benzodiazepine receptor densities. This implies that the metabolic reduction seen during iso¯urane anaesthesia was not mediated through GABAergic mechanism. However, this hypothesis appears to be in disagreement with the aforementioned ®ndings of Gyulai, 32 which emphasize the role of GABAergic transmission in mediating iso¯urane anaesthesia. However, based on their own experimental results, Alkire and co-workers did not completely rule out GABAergic mechanisms in mediating iso¯urane anaesthesia. 8 Another ®nding of Alkire's study was an iso¯urane-induced reduction in glucose metabolism that correlated with muscarinic (acetylcholine) binding density (r=0.85, P=0.03; Fig. 3 ). Brain metabolism was less decreased during iso¯urane anaesthesia in those regions that had more muscarinic receptors. This seems to indicate that regions with higher muscarinic receptor density are less sensitive to iso¯urane, suggesting antagonistic actions of iso¯urane and acetylcholine on cerebral metabolism. 8 The correlation of iso¯urane-induced reductions in glucose metabolism with muscarinic binding density is a highly interesting ®nding, as muscarinic signaling in the central nervous system is known to be involved in modulation of consciousness and tend to enhance wakefulness. 20 A recent PET study of the baboon brain provided further evidence for a more complex mechanism mediating inhalation anaesthesia. 33 Gyulai and co-workers found that the regional reduction in CMRGlu caused by halothane anaesthesia was not directly linked to GABA A -receptor density. This ®nding suggested a mechanism of halothane action other than a pure GABA A ergic one to be responsible for the depression of glucose metabolism. However, halothane and the GABA A -receptor agonist muscimol caused a nearly similar metabolic reduction in all regions investigated. This metabolic reduction was signi®cantly increased by a combination of both agents. In contrast to the lack of a signi®cant correlation during halothane alone, the changes in regional glucose metabolism induced by either muscimol or muscimol/halothane showed a signi®cant positive correlation with GABA A -receptor density, suggesting a GABA A receptor-associated mechanism in mediating neuronal inhibition by halothane.
In summary, the recently published studies are in support of the hypothesis that in vivo effects of anaesthetics are mediated at least in part through GABAergic mechanisms. Furthermore, some of these studies indicate a more complex mechanism for volatile agents in comparison with propofol in producing metabolic suppression during anaesthesia. With the expected further development in imaging techniques, 37 47 PET will be an indispensable tool to get better insights in the molecular mechanism producing anaesthesia in vivo.
PET studies of analgesic drug effects
Opioids and nitrous oxide are administered routinely as a component of clinical anaesthesia. Although these drugs are not anaesthetics, they are commonly used as an analgesic component of balanced anaesthesia. In addition to their analgesic effects, they produce dose-dependent sedation. The clinical importance of these agents is a good reason to illustrate the potential of modern brain imaging techniques in elucidating the supraspinal mechanism of opioid and nitrous oxide analgesia in humans. 41 Painful stimulation with noxious stimuli causes activation in a variety of different brain regions including the anterior cingulate cortex, somatic cortex, thalamus, prefrontal areas, parietal areas, and parts of the motor system as discussed in a recent review article by Peyron. 53 The neural response in the somatic areas is known to be related to sensorydiscriminative aspects of pain processing. Thalamic activation is assumed to be the result of a general arousal reaction induced by pain, whereas the response to noxious stimulation in the anterior cingulate cortex appears to participate in the affective and attentional components of pain sensation. Parts of the parietal and prefrontal cortices were proposed to re¯ect attentional and memory networks activated by noxious stimulation. Also often found to be activated by pain were motor-related areas such as the striatum, cerebellum, and the supplementary motor area. Activation of theses areas is assumed to re¯ect painassociated escape reactions.
Brain regions closely linked to pain processing also demonstrate changes in their functional state during analgesic procedures. In a recent H 2 15 O PET study, remifentanil exhibited dose-dependent changes in rCBF in parts of the distributed pain-processing network. 62 During low doses (0.05 mg kg ±1 min ±1 ), remifentanil induced an increase in rCBF in the prefrontal cortices, inferior parietal cortices, and the supplementary motor area. Increasing the dose (0.15 mg kg ±1 min ±1 ) caused further rCBF increases mainly in the anterior cingulate cortex, a region that frequently has been reported to be activated in pain studies, 19 53 and in the caudal periventricular grey and the transition zone of the medial part of the occipital lobe.
These ®ndings for remifentanil are partly in agreement with two previous PET studies of fentanyl action. 1 23 In both studies fentanyl caused a signi®cant increase in CBF in the anterior cingulate cortex. Besides this consistent ®nding, various other brain regions associated with pain processing exhibited changes in CBF after fentanyl administration. In addition to anterior cingulate activation, fentanyl caused a signi®cant increase in CBF in parts of the prefrontal cortex, right motor cortex, and caudate nuclei, whereas a signi®cant decrease was found in parts of the left prefrontal cortex, right temporal cortex and bilaterally in the thalamus and in the left posterior cingulate cortex. These results provide a good description of the effect of fentanyl on speci®c neural structures. To understand opioidinduced pain relief, however, the drug effect on paininduced brain activation needs to be investigated. Adler and co-workers 1 assumed that fentanyl would cause a suppression of pain evoked cerebral rCBF response. To con®rm this hypothesis, they investigated the effect of fentanyl on CBF in the presence or absence of noxious stimulation using H 2 15 O PET. In their study painful stimulation caused a CBF increase in the anterior cingulate cortex, right supplementary motor area, left thalamus, and left inferior frontal cortex. Fentanyl augmented the pain-induced activation in the supplementary motor area and the left inferior frontal cortex, whereas alterations in the CBF response of the anterior cingulate and thalamus were not reported. This phenomenon was accompanied by signi®cant pain relief. Therefore, the authors argued that the supplementary motor area and left inferior frontal cortex possibly re¯ected the neuroanatomical correlates of fentanyl analgesia. It is important to note that these results contradict the assumption of a speci®c fentanyl-associated suppression of paininduced brain stimulation.
Despite the current controversies regarding the use of nitrous oxide its antinociceptive and hypnotic potencies are still exploited during general anaesthesia. Breathing of nitrous oxide was reported to be associated with an increase in rCBF in the anterior cingulate cortex. 30 In order to further explore the supraspinal structures involved in mediating nitrous oxides antinociceptive properties, the effects of the drug on pain relief were studied. 31 Consistent with other studies 53 painful stimulation produced cerebral activation in the thalamus, anterior cingulate cortex, and supplementary motor area, re¯ecting the various aspects of pain processing. Breathing of 20% nitrous oxide abolished the activation in these areas during painful stimulation. In addition, it was associated with a CBF increase in the contralateral infralimbic and orbitofrontal cortices, suggesting a contribution of both regions to the antinociceptive effects of nitrous oxide.
In summary, the studies described above revealed parts of the neuroanatomical pathways that are important for the reduced intensity and response to pain after opioid and nitrous oxide application. Administration of opioids or nitrous oxide during painful stimulation caused deactivation in the thalamus and activation in the anterior cingulate cortex. These areas therefore appear to be targets for opioid and nitrous oxide analgesia. The observed differences in the pattern of rCBF activation caused by the analgesics further suggests that opioids and nitrous oxide modulate pain perception by affecting different neural circuits.
fMRI studies of anaesthetic action
Despite the great potential of fMRI for investigating the effect of anaesthetics on task-induced brain activation in humans only a small number of studies have been reported up to now.
12 34 44 Antognini and co-workers 12 investigated the effects of iso¯urane on processing of somatosensory stimuli. Noxious (electrical shock) and innocuous stimuli (tactile stimulation) were applied in the awake state and during different levels of iso¯urane anaesthesia. Both tactile and electric shock stimulation caused a signi®cant activation in the primary and secondary somatosensory cortex while subjects were awake. At a low anaesthetic concentration (0.7%) the response to tactile stimuli and light electric shock was greatly diminished. However, at supramaximal electrical stimulation stimulus processing in the caudate nucleus and the thalamus was still observed. The authors suggested that this activation might re¯ect an escape reaction to the noxious stimulus, as it is known that the caudate nucleus is possibly involved in coordination and initiation of motor activities. The dose-dependent response to the different stimuli suggests a subcortical site of action wherein iso¯urane prevents movements in response to noxious stimulation. The preserved functional response at the thalamic level during low-dose iso¯urane anaesthesia is consistent with the above-mentioned ®ndings for propofol. 15 It shows that cortical processing of a stimulus is already abolished during low-dose anaesthesia, whereas higher doses are required to shut down the thalamus. This might indicate similar effects of both drugs on thalamocortical transmission of sensory information to the cortex.
Martin and co-workers investigated the effects of the i.v. barbiturate thiopental and found a dose-dependent decrease in functional activation evoked by passive visual stimulation in the striate cortex. 44 After i.v. administration of 150 mg thiopental, activation in the striate cortex was still present, but considerably smaller in size compared with the awake state. The reduction in BOLD contrast was related to the ratio of amount of thiopental administered and the subject's body weight. Forty-®ve minutes after injection of the anaesthetic, cortical activation almost reached baseline. Unfortunately, these ®nding were not correlated with any behavioural data or indicator of cognitive performance. Therefore, it is not possible to interpret the importance of the remaining activation in the context of perception and processing of the stimulus or of depth of anaesthesia during imaging.
Heinke and Schwarzbauer investigated the effect of subanaesthetic concentrations of iso¯urane (0.42 vol%) on brain activation induced by a visual search. 34 The main ®nding was that iso¯urane affected task-induced brain activation in speci®c neural networks rather than causing a global decrease in functional activation. In most brain regions, the study revealed no iso¯urane-related changes in task-induced brain activation. In detail, all areas associated with primary information processing (lateral geniculate nucleus, primary visual cortex, primary motor cortex) activated by the task were not affected during breathing of iso¯urane (Fig. 4) .
However, in three focal cortical regions (anterio-superior insula, left intraparietal sulcus, and right intraparietal sulcus), iso¯urane signi®cantly decreased task-induced brain activation (Fig. 5) . The affected regions in the parietal association areas are known to be involved in visuo-spatial attention, 40 63 whereas the anterior insula plays an important role in visual working memory. 18 All subjects were conscious and able to respond to the stimulus, however, average reaction time and error rate were signi®cantly increased demonstrating an impairment of cognitive performance. Considering the iso¯ur-ane-related decrease in task-induced activation in the parietal association cortex and the insula, the observed deterioration of cognitive performance was interpreted as a selective impairment of attention and working memory processes in the visual domain.
The effect of iso¯urane on task-induced activation is dependent on the dose of the anaesthetic agent. At 0.3% Logothetis and co-workers found no signi®cant iso¯urane-related changes in the monkey brain during visual stimulation. 43 At a comparable concentration Heinke and Schwarzbauer 34 observed a signi®cant decrease in taskinduced activation in three distinct cortical regions of the human brain; however, most brain regions were not affected by iso¯urane (Figs 3 and 4) . No activation was found at 1.3% in the human somatosensory cortex during sensory stimulation 12 and at 2.0% in the monkey cortex during visual stimulation.
In summary, the results obtained in the different iso¯urane-related fMRI studies are consistent with the view that anaesthetics impair cognitive function, stimulus processing, and consciousness in a gradual fashion. 9 21 At very low concentrations (0.3%) iso¯urane exhibited no effect on cerebral activation in the monkey brain. 43 At a comparable concentration, Heinke and Schwarzbauer found a signi®cant decrease in stimulus-induced activation in three distinct cortical regions, and a preserved activation in the primary cortices and at the thalamic level. 34 Preserved subcortical activation (thalamus, caudate nucleus) during noxious stimulation was found when iso¯urane was administered in a concentration that causes unconsciousness. During higher concentrations, required to achieve immobility to noxious stimuli, no cortical, or subcortical activation was detected using fMRI.
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Conclusions
General anaesthesia is characterized by loss of consciousness, amnesia, and immobility in response to noxious stimuli. The question of how different anaesthetics produce these behavioural changes is of fundamental interest in anaesthesia research. Initial results have been reported in recent PET and fMRI studies. Key brain structures have been identi®ed, which seem to play an important role in understanding the observed behavioural changes during anaesthesia. Modern PET ligand technology offers the unique opportunity to investigate the question of how anaesthesia modulates different receptor systems in the human brain. For almost all neurotransmitter systems assumed to be involved in anaesthetic action, radioligands have become available paving the way for a rapid progress in this ®eld of research.
Anaesthesia research is also expected to bene®t from a combination of PET or fMRI with electro-and magnetoencephalographic methods that provide a temporal resolution in the millisecond range. Such complementary measurements may further clarify whether anaesthetics affect cognitive function in a gradual fashion or if speci®c changes in the behavioural state are dramatic events occurring over periods of milliseconds as recently suggested. 58 
